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Implication Statement
Sevoflurane enhances cardiac preconditioning induced by regular ethanol consumption, an
effect, mediated in part by PKC and mitochondrial KATP channels. Modulation of NOS
expression by regular ethanol consumption may also play a role in this enhanced
cardioprotection.

Abstract
Background: Volatile anesthetics and regular ethanol consumption induce cardioprotection
mimicking ischemic preconditioning. We investigated whether sevoflurane enhances ethanol
preconditioning and whether inhibition of protein kinase C (PKC) and mitochondrial KATP
channels attenuated this enhanced cardioprotection. The effects of regular ethanol consumption
on expression of inducible (iNOS) and endothelial (eNOS) nitric oxide synthase were determined.
Methods:

Isolated perfused guinea pig hearts underwent 30 min global ischemia and 120 min

reperfusion (Control:CTL). The ethanol group (EtOH) received 2.5% ethanol in their drinking
water for 6 weeks. Anesthetic preconditioning was elicited by 10 min exposure to sevoflurane (1
MAC; 2%) in ethanol (EtOH+SEVO) or non-ethanol (SEVO) hearts. PKC and mitochondrial
KATP channels were inhibited with chelerythrine (CHE) and 5-hydroxydecanoate (5-HD)
pretreatment, respectively. Contractile recovery was assessed by monitoring of left ventricular
developed (LVDP) and end-diastolic (LVEDP) pressures. Infarct size was determined by
triphenyltetrazolium chloride staining. Expression of iNOS and eNOS were determined by
Western blot analysis.
Results: After ischemia-reperfusion, hearts from the EtOH, sevoflurane (SEVO), and
EtOH+SEVO groups had higher LVDP and lower LVEDP compared with CTL. Infarct size was
reduced in EtOH and SEVO hearts compared with CTL (27% and 23% vs. 45%, respectively,
p<0.001). Sevoflurane further reduced infarct size in EtOH hearts (27% vs. 15%, p<0.001). CHE
and 5-HD abolished cardioprotection in both SEVO and EtOH cardioprotected hearts. iNOS
expression was reduced and eNOS expression was increased in EtOH hearts.
Conclusions: Sevoflurane enhances cardiac preconditioning induced by regular EtOH
consumption. This effect is mediated in part by modulation of PKC and mitochondrial KATP
channels, and possibly by altered modulation of NOS expression.
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Introduction
Volatile anesthetics induce cardiac preconditioning in a manner similar to ischemic
preconditioning.1 Since Kersten et al.2, first documented anesthetic preconditioning with
isoflurane, investigators have sought to elucidate the involved mechanisms mediating this
cardioprotection. Recently, sevoflurane was shown to confer additional cardioprotection to
late ischemic preconditioning, mediated via mitochondrial KATP channels.3 These data
suggests that sevoflurane may enhance cardioprotection in myocardium, which is already
preconditioned.
Epidemiological studies have shown that mortality rates for people who regularly
drink alcohol in moderation are lower than in abstainers, primarily due to decreased fatal
ischemic heart disease.4-7 Further, moderate alcohol consumers have lower mortality from
myocardial infarction compared with abstainers.8 These beneficial cardiac effects may be
due to the pleiotropic effects of ethanol on lipids9, platelets, and fibrinolytic activity.10,11 We
have demonstrated that regular ethanol consumption renders hearts more tolerant to
ischemia-reperfusion injury, to a degree similar to acute ischemic preconditioning.12-14 We
found this ethanol-induced preconditioning is mediated through myocyte adenosine A1
receptor12,13 and protein kinase C (PKC) activation.14 Ethanol and volatile anestheticsinduced cardiac preconditioning, thus, appear to share common signaling pathways. Guiraud
et al.15, confirmed that the combination of ethanol and ischemic preconditioning were
synergistic in reducing infarct size.
We hypothesized that anesthetic preconditioning with sevoflurane would enhance
ethanol-induced myocardial preconditioning, and that this effect is potentially mediated by
PKC activation and modulation of mitochondrial KATP channels.16 Both sevoflurane and
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acute ethanol exposure increase nitric oxide release.17,18 Thus, we examined the effect of
chronic ethanol exposure on the expression of inducible and endothelial nitric oxide
synthases (iNOS and eNOS).
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Methods
This study was conducted in accordance with the Guidelines for Animals Research
at Osaka Dental University (ODU), and with the approval of the Animal Experiment
Committee of ODU, Osaka, Japan. Male Hartley guinea pigs were fed Lab Diet (RC4TM,
Oriental Yeast, Tokyo, Japan) and given water ad libitum.

Isolated Heart Perfusion and Measurement of Function
Animals weighing 650-700g were given heparin (1000 units i.p.), then anesthetized
with pentobarbital (60 mg/kg i.p). The hearts were excised and immediately arrested in cold
isosmotic saline containing 20 mmol/L KCl. The aorta was cannulated and the isolated
hearts perfused at 70 mmHg on a nonrecirculating isovolumic perfused heart apparatus,
using a Krebs-Henseleit (KH) perfusate (mmol/L): 118 NaCl, 4.0 KCl, 2.52 CaCl2, 24.8
NaHCO3, 1.7 MgSO4, 1.2 KH2PO4, 11.0 glucose, 0.5 EDTA and 8 units/L insulin. The
perfusate was insufflated continuously with 95%O2/5%CO2. The hearts were paced at 240
beats/min using platinum-tipped electrodes connected to a Grass Instruments (Quincy, MA,
USA) SD-5 stimulus generator. Left ventricular developed pressure (LVDP) was measured
from a 2.5 French, high-fidelity micromanometer (Nihon-Kohden, Tokyo, Japan) passed
into a compliant latex balloon inserted into the LV, and recorded on a PowerLab 2/20 Data
Recording System (ADInstruments, Hayward, Australia). The balloon was connected to a
Y-adapter with one end used to advance the micromanometer and the other used to fill the
LV balloon with bubble-free water to an end-diastolic pressure (LVEDP) of 10 mmHg. The
maximum rate of increase of LV pressure (+dP/dtmax) and the minimum rate of decrease of
LV pressure (-dP/dtmin) were calculated using ChartTM5 (ADInstruments). Coronary flow
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(CF) was measured by collecting effluent. Global ischemia was achieved by clamping the
aortic inflow line. Temperature of the heart was continuously monitored by a digital
thermometer (PTW-100A, Unique Medical, Japan). During ischemia, hearts were
maintained at 37 °C by enclosure in a water-jacketed air chamber. Warmed perfusate kept in
the lower part of the chamber saturated the air with humidity and prevented cooling by
evaporation.

Experimental Protocol
Animals were assigned to one of 8 groups (n=10 each; Figure 1). Animals were
initially given 1.25 % ethanol in their drinking water for 1 week and then 2.5 % ethanol for
6 weeks. Serum ethanol levels at time of sacrifice were measured by gas chromatography
(Shimadzu, Kyoto, Japan). Liver enzymes were measured to rule out the possible liver tissue
damage.
After a 20 min equilibration, baseline LVDP, LVEDP and CF were recorded. All
hearts were subjected to 30 min of ischemia followed by 120 min of reperfusion. Anesthetic
preconditioning was elicited by administration of sevoflurane (2%) for 10 min followed by
10 min washout before ischemia. Sevoflurane was insufflated by passing the
95%O2/5%CO2 gas mixture through a calibrated vaporizer (ACOMA, Tokyo, Japan).
Samples of coronary perfusate were collected anaerobically from the aortic cannula for
measurement of sevoflurane concentration by an organic vapor sensor (OSP, Saitama,
Japan). To investigate the role of PKC and mitochondrial KATP channels activation, their
inhibitors chelerythrine (CHE) and 5-hydroxydecanoate (5-HD) were administered for 20
min, starting 10 min before sevoflurane (EtOH+SEVO+CHE, EtOH+SEVO+5HD) or saline
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vehicle (CTL+CHE, CTL+5HD) administration. Chelerythrine (Alexis-Calbiochemicals,
Tokyo, Japan) and 5-HD (Sigma Chemicals, St. Louis, MO, USA) were dissolved in
distilled water, and added to the KH perfusate to a final concentration of 10 µM and 200
µM, respectively. We performed experiments in the following order: first a CTL, followed
by ETOH, SEVO, ETOH+SEVO, CTL+CHE, and so forth until the first series of
experiments were completed. This sequence was repeated a total of ten times.

Determination of Myocardial Infarct Size
At the end of experiments, the hearts were quickly frozen at –80 °C for 15 min, then
sliced into 2 mm thick transverse sections from apex to base (6 slices/heart). After removing
the right ventricle and defrosting, each slice was weighed and incubated at 37 °C with 1%
triphenyltetrazolium chloride (Sigma Chemicals) in phosphate buffer (pH 7.4) for 10 min
and then fixed in 10% formalin for at least 5 h to distinguish red stained viable tissue from
pale unstained necrotic tissue.19 Each slice was photographed and the necrotic area was
determined using Adobe Photoshop® CS (Adobe, CA, USA) and multiplied by the weight of
the slice, then expressed as a fraction of left ventricle.

Western Blot Analysis
Separate experiments were performed (n=4 in each group) to examine iNOS and eNOS
expression. Myocardial tissue samples were collected before ischemia, and homogenized in
ice-cold homogenizing buffer containing in mM: 250 sucrose, 20 HEPES (pH 7.5), 10 KCl, 2
EGTA, 2 MgCl2, 25 NaF, 50 β-glycerophosphate, 1 Na3VO4, 1 PMSF, 1% Triton X and
protease inhibitor leupeptin (10 µg/ml). The homogenate was centrifuged at 1000g and 4 °C
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for 5 min. The supernatant was re-centrifuged at 10000g and 4 °C for 15 min. The protein
concentration was estimated with a Bradford assay. Equivalent amounts (50 µg) of protein
samples were loaded and separated on a 5-10% SDS-PAGE gradient gel, then electrically
transferred overnight to a PVDF membrane (Millipore Co., Billerica, USA). After blocking
with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), the
membranes were incubated for 2 hr at 4 °C in TBS-T containing 5% milk and 1:200 dilution
of rabbit primary antibody for iNOS and eNOS (H-174 and H-159, Santa Cruz Biotechnology,
USA). Membranes were incubated with a 1:1000 dilution of horseradish peroxidase–labeled
anti-rabbit immunoglobulin G (NA 934V, GE Healthcare, UK). The same blot was stripped
and re-blotted with antibodies to α-tubulin to confirm equal protein loading. Bound antibody
signals were detected with enhanced chemiluminescence (Pierce Biotechnology, IL, USA) and
visualized using VersaDoc 5000® Imaging System (Bio-Rad). Quantitative analysis of the
band densities was performed by Quantity One® software (Bio-Rad).
Statistical Analysis
All data are expressed as mean±SD. Two-factor repeated-measures analysis of
variance was used to evaluate differences over time between groups. If differences were
observed, a Tukey post-hoc test was used to confirm the significance of differences between
groups. The differences in expressions of iNOS and eNOS were determined by unpaired
Student’s t test. Power analysis demonstrated a sample size of n=10 hearts per group was
sufficient. A value of p<0.05 was considered statistically significant.
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Results
Of a total of 92, 10 hearts were not used secondary to intractable ventricular
fibrillation after reperfusion (four in CTL, three in CTL+CHE, two in CTL+5HD and one
EtOH+SEVO+CHE) and 2 hearts were not used due to aortic rupture. Additional hearts
were studied until each group had n=10 successful experiments. There was no significant
difference in body weight among groups. Serum ethanol levels at time of sacrifice was
2.7±0.5 mmol/L. Ethanol was not detected in the effluent of the 10 EtOH hearts sampled
after 50 min washout but before ischemia or sevoflurane exposure. There was no difference
in liver enzymes levels between EtOH and CTL animals. The concentration of sevoflurane
in the coronary perfusate after 10 min of exposure was 0.36±0.09 mM. Sevoflurane was not
detected in the effluent during the baseline, ischemic, and reperfusion periods.

Hemodynamics
Baseline LVDP, +dP/dtmax, -dP/dtmin and CF were similar among the 8 groups.
Administration of sevoflurane or treatment with CHE and 5-HD did not significantly affect
LVDP or CF. Recovery of LVDP was greater in EtOH, SEVO, and EtOH+SEVO compared
with CTL throughout the reperfusion period. Recovery of LVDP in EtOH+SEVO hearts was
abolished by administration of CHE and 5-HD. Treatment with CHE and 5-HD alone did not
affect the recovery of LVDP. LVEDP increased to 600% of baseline in CTL after ischemiareperfusion. The increase in LVEDP was significantly less in EtOH, SEVO, and
EtOH+SEVO compared with CTL hearts during reperfusion period. LVEDP in CHE and 5HD groups was similar to that of CTL hearts. Treatment with CHE and 5-HD alone did not
affect the increased LVEDP.

13

All groups had reduced +dP/dtmax

after reperfusion compared with baseline.

Recovery of +dP/dtmax was significantly greater in SEVO, EtOH and SEVO+EtOH
compared with CTL hearts, but not in hearts pretreated with CHE and 5-HD. Changes of dP/dtmin during the reperfusion period were similar to those of +dP/dtmax. There was no
significant difference in CF among all groups throughout the experiment. This suggests that
changes in CF could not account for the improved contractile recovery of SEVO or ETOH
hearts (Table 1).

Myocardial Infarct Size
Myocardial infarct size in EtOH and SEVO groups was significantly reduced by
approximately 50% compared with control hearts (EtOH:27±6%, SEVO:23±7% vs.
CTL:45±11%, p<0.001). The administration of sevoflurane in EtOH hearts decreased infarct
size compared with EtOH alone (EtOH+SEVO:15±4%, vs. EtOH: 27±6%, p<0.001).
Myocardial infarct size in EtOH and SEVO hearts pretreatment with CHE and 5-HD was not
different

compared

with

CTL

hearts

(EtOH+SEVO+CHE:44±12%,

p=0.777,

EtOH+SEVO+5-HD:45±9%, p=0.852 vs. CTL). Treatment with CHE and 5-HD alone did
not affect the infarct size compared with the CTL group (p=0.884; 0.355, respectively, vs.
CTL) (Figure 2).

Western Blot analysis
The densities of iNOS and eNOS were normalized against that of CTL. Chronic
EtOH consumption increased expression of eNOS whereas it reduced expression of iNOS
compared with the CTL groups (Figure 3). Ethanol-treated and CTL hearts showed similar
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iNOS and eNOS expression in the presence of CHE and 5-HD with and without sevoflurane
exposure (data not shown).
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Discussion
We found that pretreatment with sevoflurane and regular ethanol consumption
equally preconditioned hearts against ischemia-reperfusion injury. Furthermore, sevoflurane
enhanced the cardioprotective effect of regular ethanol consumption resulting in smaller
infarct size. This protection was abolished by inhibiting PKC or mitochondrial KATP
channels, suggesting their role in mediating the observed cardiac preconditioning. Finally,
we found that regular ethanol consumption increased eNOS expression and reduced iNOS
expression. Our finding that hearts treated with sevoflurane or ethanol showed similar
improved functional recovery, demonstrated by increased LVDP and lower LVEDP, as well
as a nearly 50% decrease in infarct size, following ischemia-reperfusion is consistent with
previous reports.12,20,21 We observed that despite a significant reduction of myocardial infarct
size induced by the combination of ethanol and sevoflurane, compared with either
preconditioning therapy alone, recovery of LVDP during reperfusion was comparable among
SEVO, EtOH and SEVO+EtOH hearts. This disparity between the functional recovery and
infarct size might be explained by myocardial stunning from global ischemia that affected a
greater area of the LV than that susceptible to infarction.22,23
A new finding of this study was that ethanol-induced preconditioning is enhanced by
anesthetic-induced preconditioning. A possible mechanism for this effect may be that
ethanol does not completely activate the signal transduction pathways eliciting
cardioprotection. We previously demonstrated that exposure to 2.5 % ethanol for 6 weeks
reduces ischemia-reperfusion injury to the same degree as 5%, 10%, and 20% ethanol for 6
to 12 weeks.12 Thus, the ethanol dose used in the present study should induce the maximum
ethanol-induced cardiac protection. Similarly, the sevoflurane dose (2%) used in the present
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study has been previously shown to produce the maximum cardiac protection.24 The additive
preconditioning effect by the combination of sevoflurane and ethanol suggests that there are
some differences in either their mechanisms of action or degree of signaling activation.
Opening of KATP channels is an important step in the signal transduction cascade of
cardiac protection from both volatile anesthetics21 and chronic ethanol exposure.25 For
example, Zaugg et al.26, demonstrated that sevoflurane increased mitochondrial flavoprotein
oxidation, an index of mitochondrial KATP channel activity, and that this effect was
completely abolished by chelerythrine (2 µM) in rat cardiomyocytes. Mitochondrial KATP
channels are activated by NO27, a key mediator in late ischemic preconditioning.28 Others
have shown that preconditioning with sevoflurane enhances the increased NO effluent
induced by bradykinin and nitroprusside in isolated guinea pig hearts.17 Moreover, ethanol
consumption increases serum NO production 30 min after drinking in humans.29 Our data
and prior reports suggest that increased eNOS expression due to chronic ethanol
consumption could result in increased NO production. This is consistent with a previous
study demonstrating that ethanol increases NO production through modulation of eNOS
expression.18 Recently, the importance of eNOS in myocardial ischemic protection was
demonstrated in an eNOS knockout mice model.30 Thus, augmentation of mitochondrial
KATP channel activity by increased NO with the combination of sevoflurane and chronic
ethanol consumption might explain the additive cardioprotection in SEVO+EtOH hearts.
Previous experiments suggest that inflammation plays a role ischemia-reperfusion
injury.31 NO derived from iNOS mediates cardiac dysfunction by inducing production of
pro-inflammatory cytokines.32 Cytokines such as interleukin-1β, interleukin-6, and tumor
necrosis factor-alpha (TNF-α) are up-regulated rapidly in response to myocardial ischemia.33
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Sevoflurane has been shown to reduce the production of TNF-α in patients undergoing
coronary bypass surgery.34 Interestingly, a recent study found that the late phase of ethanol’s
myocardial preconditioning correlated with reduced leukocyte-endothelial cell adhesive
interactions, suggesting an anti-inflammatory effect.35 In the present study, with a
crystalloid-perfused heart, leukocyte-endothelial cell adhesive interactions, though, is not a
factor. Nevertheless, EtOH hearts demonstrated reduced iNOS expression before ischemia
compared with CTL. Thus, regular ethanol consumption could attenuate the inflammatory
response to myocardial ischemia resulting from increased NO production via iNOS.
Although iNOS is thought to be absent in myocytes under physiologic conditions, there is
evidence that iNOS is present in small vessel endothelium, vascular smooth muscle cells,
and immune cells that infiltrate the heart.36
Recent studies demonstrate that acute (as opposed to chronic) ethanol exposure fails
to exert a cardioprotection when ethanol is present during ischemia-reperfusion.37 Although
not withdrawn from the drinking water before sacrifice in this study, serum ethanol levels
were low (2.7±0.5 mmol/L) at the time of sacrifice. Ethanol was washed out prior to
ischemia using a crystalloid ethanol-free buffer. Ethanol was not detected after 50 min
perfusion in the effluent. Ethanol freely diffuses in myocytes. Thus, tissue levels of ethanol
were likely negligible at the time of study.
A limitation of the present study is that we did not directly measure PKC levels and
mitochondrial KATP channel activity before and during ischemia-reperfusion. The doses of
CHE and 5-HD used in the present study have been previously found to reduce PKC levels
and inhibit mitochondrial KATP channel activity, respectively.14,38 Furthermore, we and other
investigators have previously shown that the same concentrations of CHE and 5-HD inhibit
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the preconditioning-like effects of ethanol or sevoflurane alone.14,25,38 Prolonged ingestion of
ethanol may lead to changes in heart rate and blood pressure. Although we did not measure
heart rate or blood pressure prior to sacrifice in this study, a previous study demonstrated
that feeding 10 % ethanol (a much higher dose) for 40 weeks to guinea pigs did not alter
hemodynamics compared with control39. Finally, animals were not randomized to each study
group although the order of study was standardized.
In conclusion, sevoflurane enhances cardiac preconditioning induced by regular
ethanol consumption. Our findings suggest that PKC and mitochondrial KATP channels play
a role in mediating this cardioprotection. NOS expression is altered by regular ethanol
consumption.
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Table Legend
Table 1: Data are presented as mean ± SD. LVDP=left ventricular developed pressure;
LVEDP=left ventricular end-diastolic pressure; CF=coronary flow; +dP/dtmax=maximum
rate of increase of LV pressure; -dP/dtmin= maximum rate of increase of LV pressure;
CTL=control;

EtOH=ethanol;

SEVO=sevoflurane

hydroxydecanoate. *p<0.05 vs. CTL , n=10 for each group

CHE=chelerythrine;

5-HD=5-
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Figure Legends

Figure 1: Schematic illustration of the experimental protocol of this study. All hearts were
subjected to 30 min global ischemia followed by 120 min reperfusion. Anesthetic
preconditioning (APC) was elicited by administration of sevoflurane (2% or 1 MAC) for 10
min with a 10 min washout period. Ethanol-treated animals received 2.5% ethanol in their
drinking

water

for

6

weeks.

CTL=control;

EtOH=ethanol;

SEVO=sevoflurane;

CHE=chelerythrine, PKC inhibitor; 5-HD=5-hydroxydecanoate, mitochondrial KATP channel
inhibitor

Figure 2: Infarct size as a percentage of LV in eight groups. Treatment with sevoflurane (1
MAC) and 2.5 % ethanol for 6 weeks equally reduced infarct size compared with control.
The combination of sevoflurane and 2.5 % ethanol conferred a further reduction of infarct
size. This additional cardioprotective effect was abolished by CHE and 5-HD in
SEVO+EtOH. 5-HD and CHE treatment alone did not affect infarct size. Data are presented
as mean ± SD. *p<0.001 vs. CTL, #p<0.001 vs. EtOH and SEVO

Figure 3: Western blot analysis of iNOS and eNOS from left ventricular samples before
ischemia in control and ethanol-treated hearts (n=4 for each group). In ethanol-treated
hearts, iNOS expression was significantly reduced and eNOS expression was significantly
increased compared with control. *p<0.05 vs. CTL
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Table 1. Hemodynamic Variables
baseline
-60
LVDP (mmHg)
CTL
EtOH
SEVO
EtOH+SEVO
CTL+CHE
EtOH+SEVO+CHE
CTL+5-HD
EtOH+SEVO+5-HD
LVEDP (mmHg)
CTL
EtOH
SEVO
EtOH+SEVO
CTL+CHE
EtOH+SEVO+CHE
CTL+5-HD
EtOH+SEVO+5-HD
CF (ml)
CTL
EtOH
SEVO
EtOH+SEVO
CTL+CHE
EtOH+SEVO+CHE
CTL+5-HD
EtOH+SEVO+5-HD
+dP/dtmax (mmHg-Es-1)
CTL
EtOH
SEVO
EtOH+SEVO
CTL+CHE
EtOH+SEVO+CHE
CTL+5-HD
EtOH+SEVO+5-HD
-dP/dtmin (mmHg-Es-1)
CTL
EtOH
SEVO
EtOH+SEVO
CTL+CHE
EtOH+SEVO+CHE
CTL+5-HD
EtOH+SEVO+5-HD

113±17
104±14
101±13
110±16
109±13
100±8
107±16
111±7
10±0
10±0
10±0
10±0
10±0
10±0
10±0
10±0
28±7
27±4
31±7
26±6
28±8
28±7
29±5
27±4
1735±310
1433±242
1479±251
1588±257
1566±232
1442±145
1635±219
1653±137
-1470±252
-1197±274
-1230±181
-1318±192
-1310±149
-1321±155
-1473±149
-1467±151

(CHE or 5HD)
+SEVO/SEVO

-40

100±12
106±20
108±15
99±12
108±16
112±14

10±3
9±2
10±3
10±2
7±3
8±4

29±4
30±7
31±8
32±8
26±6
24±4

1492±212
1604±285
1676±297
1521±205
1683±203
1586±276

-1220±160
-1261±271
-1375±241
-1254±152
-1546±209
-1548±251

reperfusion (min)

washout
-30

30

60

120

103±12
110±17
97±17
88±18
102±17
106±14

39±7
60±13*
61±9*
66±8*
26±12
30±10
41±11
38±13

33±8
56±13*
58±8*
61±8*
27±12
29±10
39±10
35±10

26±8
47±11*
50±8*
50±9*
26±12
29±9
36±10
32±8

10±2
10±3
13±7
15±13
8±4
10±4

47±13
24±21*
24±7*
19±6*
52±20
46±17
49±12
56±18

55±18
25±21*
24±5*
20±6*
49±23
50±19
53±9
58±17

60±17
27±20*
26±7*
25±11*
48±24
49±20
55±10
57±19

27±4
25±5
26±9
26±9
26±5
22±3

27±9
26±10
25±7
21±4
21±7
20±9
28±7
22±7

28±10
26±10
25±7
20±3
21±7
20±9
28±7
21±7

28±11
25±11
24±7
20±3
20±8
19±9
27±8
21±7

1529±224
1623±232
1443±349
1368±268
1656±174
1485±259

674±218 544±168
786±185
1114±197* 1085±212* 925±179*
1019±168* 1000±156* 910±124*
1156±159* 1133±132* 953±162*
490±200 482±197
491±203
576±161 537±175
572±176
700±200 660±225
730±212
614±127 564±96
625±113

-1286±157
-1344±175
-1017±372
-1081±280
-1510±228
-1411±265

-553±141
-913±203*
-815±120*
-889±118*
-355±144
-408±142
-523±136
-524±146

-483±124
-809±190*
-771±109*
-853±114*
-367±146
-426±139
-486±113
-515±131

-389±100
-709±182*
-694±106*
-699±171*
-375±153
-413±132
-454±108
-378±356

